AMRX
Price
$9.62
Change
+$0.06 (+0.63%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
3.02B
62 days until earnings call
VTRS
Price
$10.51
Change
+$0.18 (+1.74%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
12.24B
65 days until earnings call
Interact to see
Advertisement

AMRX vs VTRS

Header iconAMRX vs VTRS Comparison
Open Charts AMRX vs VTRSBanner chart's image
Amneal Pharmaceuticals
Price$9.62
Change+$0.06 (+0.63%)
Volume$12.68K
Capitalization3.02B
Viatris
Price$10.51
Change+$0.18 (+1.74%)
Volume$168.79K
Capitalization12.24B
AMRX vs VTRS Comparison Chart in %
Loading...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. VTRS commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Buy and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (AMRX: $9.55 vs. VTRS: $10.33)
Brand notoriety: AMRX and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 109% vs. VTRS: 83%
Market capitalization -- AMRX: $3.02B vs. VTRS: $12.24B
AMRX [@Pharmaceuticals: Generic] is valued at $3.02B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.24B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than AMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 5 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • AMRX’s TA Score: 5 bullish, 4 bearish.
  • VTRS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AMRX is a better buy in the short-term than VTRS.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -0.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was +85.54%.

Reported Earning Dates

AMRX is expected to report earnings on Nov 07, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.2B) has a higher market cap than AMRX($3.02B). AMRX has higher P/E ratio than VTRS: AMRX (962.00) vs VTRS (236.20). AMRX YTD gains are higher at: 20.581 vs. VTRS (-13.813). VTRS has more cash in the bank: 406M vs. AMRX (71.5M). AMRX has less debt than VTRS: AMRX (2.58B) vs VTRS (14.5B).
AMRXVTRSAMRX / VTRS
Capitalization3.02B12.2B25%
EBITDA584MN/A-
Gain YTD20.581-13.813-149%
P/E Ratio962.00236.20407%
Revenue2.85BN/A-
Total Cash71.5M406M18%
Total Debt2.58B14.5B18%
FUNDAMENTALS RATINGS
AMRX vs VTRS: Fundamental Ratings
AMRX
VTRS
OUTLOOK RATING
1..100
2685
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
11
Undervalued
PROFIT vs RISK RATING
1..100
52100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
4243
P/E GROWTH RATING
1..100
321
SEASONALITY SCORE
1..100
3250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (11) in the null industry is significantly better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew significantly faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (52) in the Pharmaceuticals Major industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that AMRX’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as VTRS (43) in the null industry. This means that AMRX’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as AMRX (32) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
68%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
51%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCEGX15.030.18
+1.21%
BlackRock Unconstrained Equity Inv C
PSCCX28.520.26
+0.92%
PGIM Jennison Small Company C
APSGX17.560.16
+0.92%
NYLI Fiera SMID Growth Class I
HUSIX28.540.23
+0.81%
Huber Small Cap Value Inv
FZAHX232.08N/A
N/A
Fidelity Advisor Growth Opps Z

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with PAHC. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+0.10%
PAHC - AMRX
46%
Loosely correlated
+2.29%
VTRS - AMRX
43%
Loosely correlated
-2.09%
TEVA - AMRX
40%
Loosely correlated
-1.49%
COLL - AMRX
39%
Loosely correlated
-0.91%
ALKS - AMRX
38%
Loosely correlated
-3.60%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-2.09%
ELAN - VTRS
53%
Loosely correlated
+0.69%
ZTS - VTRS
46%
Loosely correlated
+0.51%
AMRX - VTRS
44%
Loosely correlated
+0.10%
EBS - VTRS
43%
Loosely correlated
-2.55%
COLL - VTRS
37%
Loosely correlated
-0.91%
More